Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.

Bulletin du cancer - 1 Feb 2015

Netter Jeanne, Lehmann-Che Jacqueline, Lambert Jerome, Tallet Anne, Lourenco Nelson, Soliman Hany, Bertheau Philippe, Pariente Benjamin, Chirica Mircea, Pocard Marc, Allez Matthieu, De The Hugues, Gornet Jean-Marc

Abstract excerpt

BACKGROUND: Survival of metastatic colon cancer (mCC) patients has considerably improved with optimization of new drugs regimen. Inactivation of TP53 pathway by TP53 mutations is observed in nearly half of colorectal tumors. The impact of such mutations has been poorly studied in the metastatic s...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Colonic Neoplasms
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Silencing

Share to Microsatellite Instability

Share to Pigmentation

Share to ras Proteins

Share to Yeasts

Source

Identifiers

PMID: 25609485
DOI: 10.1016/j.bulcan.2014.12.010

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25609485-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.PMID 25609485Read ↗

Clinical impact of TP53 mutation status on survival outcomes in metastatic colorectal cancer.Semantic proximity Read ↗

TP53 mutations in advanced colorectal cancer: the dark side of the moon.Semantic proximity Read ↗

Lack of Relationship Between Clinical Features and KRAS Mutations in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

Influence of KRAS mutations on clinical outcome in patients with curatively resected stage III colon cancer treated with adjuvant chemotherapy.Semantic proximity Read ↗

Prognostic Impact of RAS and TP53 Mutation Profiles in Metastatic Colorectal Cancer.Semantic proximity Read ↗

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy.Semantic proximity Read ↗

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.Semantic proximity Read ↗

Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma.Semantic proximity Read ↗

Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation.Semantic proximity Read ↗

Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.Semantic proximity Read ↗

The prognostic role of p53 mutations in metastatic colorectal cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.